<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909346</url>
  </required_header>
  <id_info>
    <org_study_id>UX431-CL001</org_study_id>
    <nct_id>NCT04909346</nct_id>
  </id_info>
  <brief_title>Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease</brief_title>
  <official_title>Observational Clinical Study of Anti-AAV Seroprevalence in Subjects With Ornithine Transcarbamylase Deficiency, Glycogen Storage Disorder Type Ia, and Wilson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this observational study is to evaluate the seroprevalence of anti-AAV&#xD;
      antibodies in subjects with Ornithine Transcarbamylase (OTC) deficiency, Glycogen Storage&#xD;
      Disease Type Ia (GSDIa), and Wilson Disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is primarily designed to follow a virtual model, in which Screening will take place&#xD;
      over a telephone/video call. The study will comprise a single home health visit, either on&#xD;
      the same day as Screening or within 30 days of enrollment. A safety follow-up may occur up to&#xD;
      5 days after Day 1 assessments are completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Anti-AAV8 Antibodies in Subjects with OTC Deficiency or GSDIa</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Anti-AAV9 Antibodies in Subjects with Wilson Disease</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ornithine Transcarbamylase Deficiency</condition>
  <condition>Wilson Disease</condition>
  <condition>Glycogen Storage Disease Type IA</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples for future biomarker assay development&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will include approximately equal proportions of subjects with OTC&#xD;
        deficiency, GSDIa, and Wilson Disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of OTC deficiency, GSDIa, or Wilson Disease.&#xD;
&#xD;
          -  Provide informed consent after the nature of the study has been explained, and prior&#xD;
             to any research-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to an AAV-based gene therapy.&#xD;
&#xD;
          -  Concurrent or previous participation in another Ultragenyx clinical study.&#xD;
&#xD;
          -  Recipient of a liver transplant.&#xD;
&#xD;
          -  Presence or history of any condition that, in the view of the Investigator, would&#xD;
             interfere with participation, pose undue risk, or would confound interpretation of&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceutical Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Contact: Trial Recruitment</last_name>
    <phone>1-888-756-8657</phone>
    <email>trialrecruitment@ultragenyx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HCP Contact: Medical Information</last_name>
    <phone>1-888-756-8657</phone>
    <email>medinfo@ultragenyx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Synexus Clinical Research US (Virtual Trial)</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AAV Seroprevalence Study Call Center</last_name>
      <phone>877-223-3578</phone>
      <phone_ext>89431</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

